https://pepsreview.com/articles/novo-nordisk-flags-illicit-ozempic-sellers-instagram-whatsapp PepsReview en 2026-10-16 Ozempic, Instagram, WhatsApp, illicit medicine sales, Novo Nordisk, counterfeit GLP-1, South Africa, weight loss drugs https://pepsreview.com/articles/south-africa-drugmakers-urge-police-crackdown-illegal-retatrutide-sales PepsReview en 2026-10-16 retatrutide, South Africa, illegal medicine sales, GLP-1, black market, enforcement, pharmaceutical task group, weight loss drugs https://pepsreview.com/articles/south-africa-rewrites-compounding-rules-glp1-gray-market PepsReview en 2026-10-16 compounding, South Africa, GLP-1, semaglutide, pharmacy council, SAHPRA, compounding rules, weight loss drugs https://pepsreview.com/articles/ireland-peptide-market-lab-testing-significant-impurities PepsReview en 2026-10-15 peptide impurities, peptide testing, Ireland peptide market, Melanotan purity, BPC-157 seizures, HPRA, gray market peptides, Retatrutide counterfeit https://pepsreview.com/articles/fda-reports-black-mold-contamination-chinese-glp1-ingredient-plants PepsReview en 2026-10-15 GLP-1, semaglutide, tirzepatide, FDA inspection, API contamination, peptide safety, compounding, Chinese manufacturers https://pepsreview.com/articles/clinicians-publish-first-selection-framework-fda-approved-mash-therapies PepsReview en 2026-10-15 MASH, resmetirom, semaglutide, GLP-1, FDA approval, liver fibrosis, hepatology, MASLD https://pepsreview.com/articles/fda-warning-letters-unapproved-indian-branded-semaglutide PepsReview en 2026-10-14 FDA warning letter, unapproved semaglutide, online sellers, Indian generics, GLP-1 enforcement, misbranded drugs, peptide safety https://pepsreview.com/articles/retatrutide-poison-center-exposures-nearly-double PepsReview en 2026-10-14 retatrutide, poison center, bootleg peptides, FDA death reports, grey market GLP-1, adverse events, peptide safety https://pepsreview.com/articles/verdiva-bio-terminates-oral-glp-1-weight-maintenance-trial-strategy-pivot PepsReview en 2026-10-14 Verdiva Bio, VRB-101, ecnoglutide, oral GLP-1, weight maintenance, obesity clinical trials, peptide research